Regulatory hub · UK status
Tirzepatide: UK regulatory status
Also known as: Mounjaro, Zepbound
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · Tirzepatide
Tirzepatide is a Prescription Only Medicine in the UK with MHRA marketing authorisation for type 2 diabetes and chronic weight management. It is not a controlled drug. Branded promotion to the public is prohibited under ASA and MHRA rules for POM.
Misuse of Drugs Act 1971
Tirzepatide does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
Tirzepatide is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
Tirzepatide is classified as a Prescription Only Medicine under the Human Medicines Regulations 2012. UK marketing authorisation is held by the originator manufacturer. It is dispensed through registered UK pharmacies on a valid prescription from a qualified UK prescriber.
WADA Prohibited List position
Tirzepatide is not currently named on the WADA Prohibited List. Tested athletes should consult WADA and their federation directly.
ASA advertising framing
POM medications cannot be advertised to the public under the Human Medicines Regulations 2012. UK clinics may state they offer "weight loss treatment" or "GLP-1 medications" generically; named-brand promotion to the public is prohibited.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is Tirzepatide legal in the UK?
What is the MHRA position on Tirzepatide?
Is Tirzepatide on the WADA Prohibited List?
What can UK sellers say about Tirzepatide in adverts?
Related: Tirzepatide editorial entry · UK regulatory hub.